Drug Trial Radar · NCT05347693
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
Last checked: Nov 20, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Actual
Start
Mar 24, 2022
Primary completion
Dec 10, 2024
Study completion Dec 10, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, randomised study in participants with chronic kidney disease (CKD) treated for hyperkalaemia (HK) whilst in hospital. The study will compare SZC to standard of care (SoC) with the goal of determining: * If continued use of SZC maintains normokalaemia (NK) better than SoC after participant discharge from the hospital. * If continued use of SZC after discharge will reduce HK related healthcare resource utilisation compared to SoC.
Conditions
- Hyperkalaemia
- Chronic Kidney Disease
Interventions
Sodium Zirconium Cyclosilicate (SZC)Drug
White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement. Label text will be translated into local language.
Local standard of careDrug
Local SoC in the country to be used as per local label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence (Yes/No) of NK (K+ Between 3.5 and 5.0 mmol/L, Inclusive) at 180 Days Post-dischargeTime frame: At 180 days post-discharge (Visit 10)
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Bonheiden, Belgium
Research Site
Leuven, Belgium
Research Site
Annonay, France
Research Site
Ars-Laquenexy, France
Research Site
Nice, France
Research Site
Saint-Priest-en-Jarez, France
Research Site
Bari, Italy
Research Site
Foggia, Italy
Research Site
Parma, Italy
Research Site
Pavia, Italy
Research Site
Eindhoven, Netherlands
Research Site
Algeciras, Spain
Research Site
Almería, Spain
Research Site
Badajoz, Spain
Research Site
Barcelona, Spain
Research Site
Burgos, Spain
Research Site
Getafe, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Salamanca, Spain
Research Site
San Sebastián de los Reyes, Spain
Research Site
Seville, Spain
Research Site
Talavera de la Reina, Spain
Research Site
Zamora, Spain
Research Site
Doncaster, United Kingdom
Research Site
Hull, United Kingdom
Research Site
Salford, United Kingdom
Research Site
Stevenage, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.